Patents by Inventor Peter R. Schreiner

Peter R. Schreiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8716539
    Abstract: Dinitroxylated diamantanes are suitable for being reacted with nucleophiles to form the corresponding disubstituted diamantanes. Surprisingly, at least dinitroxylated or hydroxylated diamantanes are rearranged in the presence of a strong acid and at least 4,9-nitroxylated or hydroxylated diamantanes are created. On this basis, 4,9-substituted diamantanes are able to be produced in a targeted manner by reaction with further nucleophiles.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: May 6, 2014
    Assignee: Justus-Liebig-Universitaet Giessen
    Inventors: Peter R. Schreiner, Andrey A. Fokin
  • Publication number: 20130165625
    Abstract: The disclosed invention relates to peptides incorporating 3-aminoadamantane-1-carboxylic acids. These peptides are disclosed as surprisingly possessing neurogenic and neurotrophic properties. These pharmacological activities can advantageously be utilized for restoring or maintaining neuronal function in the CNS. In particular, the compounds can be used for treatment and prophylaxis of neurodegenerative diseases, e. g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, as well as in post-acute traumatic brain injury, or cerebral ischemia.
    Type: Application
    Filed: June 22, 2011
    Publication date: June 27, 2013
    Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSEN
    Inventors: Peter R. Schreiner, Lukas Wanka
  • Patent number: 8138375
    Abstract: The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: March 20, 2012
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventors: Peter R. Schreiner, Andrey A. Fokin, Lukas Wanka, Derek M. Wolfe
  • Publication number: 20110308605
    Abstract: Provided is a fluorescent diamondoid material which when energized, either by an electric field or by high energy radiation, emits light. The light emitted is generally in the visible range. The diamondoid material can be fine tuned by internal or external doping. The fluorescent materials comprised of diamondoids, have applications in several fields. One application is in solar cells where these materials can be used to improve the overall efficiency of the device. A second application is in indoor lighting where the materials can be used to efficiently produce white light. This can be done by either using the material as a fluorescent medium for a UV light source, in an electroluminescence device, or by using the material as part of an organic light emitting diode (OLED).
    Type: Application
    Filed: January 30, 2009
    Publication date: December 22, 2011
    Applicants: Justus-Liebig-Universitaet Giessen, Leland J. Stanford Junior Univesity
    Inventors: Zhi Liu, Will Clay, Michael A. Kelly, Nicholas A. Melosh, Zhi-Xun Shen, Andrey A. Fokin, Peter R. Schreiner
  • Publication number: 20110124912
    Abstract: The invention at hand describes functionalized diols of diamondoids, in which one of the two hydroxy groups is masked by a protective group, as well as methods for producing these functionalized diols. The protective group is a group —CHR1R2, wherein R1 and R2 stand for alkyl groups and the protective group comprises at least one halogen atom. The monoethers of the diamondoid diols according to the present invention are produced by reacting the diamondoid diol with a halogenated alcohol CHOHR1R2 in the presence of a catalyst acid. The monoetherified diols allow for the targeted production of derivatives of diamondoids, for example, of the corresponding aminoalcohols and aminocarboxylic acids. For that purpose, the diamondoid monoether is reacted in a first step with a halogen nitrile in a Ritter reaction to the corresponding monoether amide.
    Type: Application
    Filed: June 2, 2009
    Publication date: May 26, 2011
    Applicant: JUSTUS-LIEBIG-UNIVERSITAT GIESSEN
    Inventors: Peter R. Schreiner, Hartmut Schwertfeger
  • Publication number: 20110082053
    Abstract: Provided is a molecular rectifier comprised of a diamondoid molecule and an electron acceptor attached to the diamondoid molecule. The electron acceptor is generally an electron accepting aromatic species which is covalently attached to the diamondoid.
    Type: Application
    Filed: January 30, 2009
    Publication date: April 7, 2011
    Inventors: Wanli Yang, Zhi-Xun Shen, Harindran C. Manoharan, Nicholas A. Melosh, Michael A. Kelly, Andrey A. Fokin, Peter R. Schreiner, Jason C. Randel
  • Publication number: 20100036153
    Abstract: The invention at hand provides at least dinitroxylated diamantanes. In addition, it provides methods for producing substituted diamantanes with high yields and selectivity. According to the invention, dinitroxylated diamantanes are suitable for being reacted with nucleophiles to form the corresponding disubstituted diamantanes. Surprisingly, it was discovered that at least dinitroxylated or hydroxylated diamantanes are rearranged in the presence of a strong acid, creating at least 4,9-nitroxylated or hydroxylated diamantanes. On the basis of this, 4,9-substituted diamantanes are able to be produced in a targeted manner by reaction with further nucleophiles.
    Type: Application
    Filed: December 4, 2006
    Publication date: February 11, 2010
    Inventors: Peter R. Schreiner, Andrey A. Fokin
  • Publication number: 20090299096
    Abstract: The invention relates to 1-formamido-adamantane derivatives of formula (I), which carry the substituents R1, R2 or R3 in 3, 5 and/or 7 position, the substituents being defined as follows: hydrogen, a linear or branched alkyl, alkenyl or alkinyl group with up to 6 C atoms, an aliphatic or aromatic, cyclic or heterocyclic hydrocarbon group with up to 10 carbon atoms, and formamides of hydrocarbons from the group of diamondoids, for example diamantane, triamantane, tetramantane and pentamantane, however, with the exception of 1-formamido-3,5-dimethyladamantane. The invention also relates to a method for the direct formation of formamide or acetamide of adamantane, adamantane derivatives with the aforementioned definition of substituents or of a hydrocarbon from the group of diamondoids, characterized by reacting the adamantane, the adamantane derivative or the diamondoid with formamide, acetamide or acetonitrile in concentrated acids, while avoiding SO3 containing sulfuric acid or 100% azotic acid.
    Type: Application
    Filed: February 20, 2007
    Publication date: December 3, 2009
    Inventors: Peter R. Schreiner, Andrey A. Fokin, Lukas Wanka, Derek M. Wolfe
  • Publication number: 20090299097
    Abstract: The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids.
    Type: Application
    Filed: February 20, 2007
    Publication date: December 3, 2009
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Peter R. Schreiner, Andrey A. Fokin, Lukas Wanka, Derek M. Wolfe
  • Publication number: 20080275112
    Abstract: The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers. The compounds based on the present invention are suitable for the utilisation as antiviral active ingredients, artificial ion channels, as well as for the therapy, diagnostics and prophylaxis of diseases in which a dysfunction of the GABA system occurs.
    Type: Application
    Filed: July 22, 2005
    Publication date: November 6, 2008
    Inventors: Peter R. Schreiner, Lukas Wanka